Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: Clinical results from a multicenter phase II trial

International Journal of Gynecological Cancer

Volumn 16, Issue 3, 2006, Pages 1075-1081

  Fiander, A N ^a   Tristram, A J ^a   Davidson, E J ^b,c   Tomlinson, A E ^d   Man, S ^a   Baldwin, P J ^e   Sterling, J C ^e   Kitchener, H C ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^e CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Anogenital neoplasia; Human papillomavirus; Intraepithelial neoplasia; Therapeutic vaccines; Vulval intraepithelial neoplasia

Indexed keywords

HYBRID PROTEIN; PROTEIN E6; PROTEIN E7; WART VIRUS VACCINE;

ADULT; AGED; ANOGENITAL INTRAEPITHELIAL NEOPLASIA; ARTICLE; BIOPSY; CANCER IMMUNOTHERAPY; CARCINOMA IN SITU; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ERYTHEMA; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; NONINVASIVE VAGINA CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; UNSPECIFIED SIDE EFFECT; VACCINATION; VACCINIA VIRUS; VULVA CARCINOMA IN SITU; WART VIRUS;

ADULT; ANUS NEOPLASMS; CARCINOMA IN SITU; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; MIDDLE AGED; PAPILLOMAVIRUS VACCINES; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 33745115850     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00598.x     Document Type: Article

References (32)

1. Jones R. The natural history of lower genital tract precancers: an historical perspective. In : MacLean AB Singer A Critchley H, eds. Lower genital tract neoplasia. London : RCOG Press, 2003.
2. Fiander A Man S. HPV vaccines. In : MacLean AB Singer A Critchley H, eds. Lower genital tract neoplasia. London : RCOG Press, 2003.
3. Davidson EJ Davidson JA Sterling JC Baldwin PJ Kitchener HC Stern PL. Association between human leukocyte antigen polymorphism and human papillomavirus 16-positive vulval intraepithelial neoplasia in British women. Cancer Res 2003 63 : 400 3.
4. Crook T Morgenstern JP Crawford L Banks L. Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. Embo J 1989 8 : 513 9.
5. Stanley M. Immune responses to human papillomaviruses. In : Sterling J Tyring S, eds. Human papillomaviruses Clinical and scientific advances. London, UK : Arnold 2001 : 38 49.
6. Gilboa E. The makings of a tumor rejection antigen. Immunity 1999 11 : 263 70.
7. Meneguzzi G Cerni C Kieny MP Lathe R. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology 1991 181 : 62 9.
8. Zinkernagel RM. Immunology taught by viruses. Science 1996 271 : 173 8.
9. Boon T Cerottini J-C Van den Eynde B van der Bruggen P Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994 12 : 337 65.
10. Ridge JP Di Rosa F Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998 393 : 474 8.
11. Schoenberger SP Toes RE van der Voort EI Offringa R Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998 393 : 480 3.
12. Borysiewicz LK Fiander A Nimako M et al. A recombinant vaccinia virus encoding human papillomavirus type 16 and type 18, e6 and e7 proteins as immunotherapy for cervical cancer. Lancet 1996 347 : 1523 7.
13. Rankin E Sommer H Schneider A et al. TA-HPV, a modified vaccinia virus carrying HPV 16 and 18 E6 and E7 proteins induces potent immunity in women with early cervical cancer. Proceedings of American Association for Cancer Research 91st Annual Meeting 2000 41 : 469.
14. Adams M Borysiewicz L Fiander A et al. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine 2001 19 : 2549 56.
15. Davidson EJ Boswell CM Sehr P et al. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res 2003 63 : 6032 41.
16. Baldwin PJ van der Burg SH Boswell CM et al. Vaccinia-expressed human papillomavirus 16 and 18 E6 and E7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin Cancer Res 2003 9 : 5205 13.
17. Smith KL Tristram A Gallagher KM Fiander AN Man S. Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18. Int Immunol 2005 17 : 167 76.
18. van der Burg SH Ressing ME Kwappenberg KM et al. Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II- restricted epitopes. Int J Cancer 2001 91 : 612 8.
19. Callan MF Steven N Krausa P et al. Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nature Medicine 1996 2 : 906 11.
20. van der Burg SH Kwappenberg KM O'Neill T et al. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine 2001 19 : 3652 60.
21. de Jong A O'Neill T Khan AY et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E6E7 fusion protein vaccine. Vaccine 2002 20 : 3456 64.
22. Davidson E Faulkner RL Sehr P et al. Effect of TA-CIN (HPV16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV16/18 E6E7). Vaccine 2004 22 : 2722 9.
23. Walboomers J Jacobs M Nindl I et al. Reliability of high-risk human papillomavirus DNA testing by GP5+/6+ PCR-EIA. Paper presented at: 17th International Papillomavirus Conference January 9 - 15, 1999 Charleston, SC.290.
24. Smyth LJ Van Poelgeest MI Davidson EJ et al. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res 2004 10 : 2954 61.
25. Palefsky J Goldstone S Neefe J. HSPE7 treatment of high-grade anal dysplasia: final results of an open-label trial and interim long-term follow-up. Paper presented at: 20th International Papillomavirus Conference October 4 - 9, 2002 Paris, France.
26. Schneider J Gilbert SC Hannan CM et al. Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. Immunol Rev 1999 170 : 29 38.
27. Tindle RW. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2002 2 : 59 65.
28. Evans EM Man S Evans AS Borysiewicz LK. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res 1997 57 : 2943 50.
29. Christensen ND Han R Cladel NM Pickel MD. Combination treatment with intralesional cidofovir and viral-DNA vaccination cures large cottontail rabbit papillomavirus-induced papillomas and reduces recurrences. Antimicrob Agents Chemother 2001 45 : 1201 9.
30. Christensen ND Pickel MD Budgeon LR Kreider JW. In vivo anti-papillomavirus activity of nucleoside analogues including cidofovir on CRPV-induced rabbit papillomas. Antiviral Res 2000 48 : 131 42.
31. Abdel Hady E Martin Hirsch P Duggan-Keen M et al. Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res 2001 61 : 192 6.
32. Jones RW Rowan DM. Spontaneous regression of vulvar intraepithelial neoplasia 2-3. Obstet Gynecol 2000 96 : 470 2.